Vaccine description | |
---|---|
Target | Cancer driven by G12D, G12V, G13D or G12C mutation in the KRAS gene |
Vaccine type | mRNA |
Clinical data | |
Routes of administration | Intramuscular |
mRNA-5671 also known as V941 is a
cancer vaccine candidate developed by
Moderna.
[1] It is a
tetravalent vaccine that targets G12D, G12V, G13D or G12C driver mutations in the
KRAS gene.
[2] It is currently being evaluated for the treatment of either
non-small cell lung cancer,
colorectal cancers with
microsatellite instability, or
pancreatic adenocarcinoma, all with confirmed KRAS driver mutations.
[3]
In 2021 Merck dropped the trial,
[4]
[5] and clinicaltrials.gov study NCT03948763 ended 2022-08-25.
[6] As of May 2024, no further progress on this vaccine has been announced.